STOCK TITAN

Sol-Gel Technologies Ltd - SLGL STOCK NEWS

Welcome to our dedicated news page for Sol-Gel Technologies (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol-Gel Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sol-Gel Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sol-Gel Technologies's position in the market.

Rhea-AI Summary
Sol-Gel Technologies, announces Padagis's submission of an ANDA for Roflumilast Cream, 0.3%, triggering a patent challenge from Arcutis Biotherapeutics. The potential generic market exclusivity could lead to significant profits. Sol-Gel and Padagis are optimistic about the market potential and are exploring ways to maximize value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (SLGL) initiates phase 3 clinical trial of SGT-610 for Gorlin Syndrome, with promising results expected by end of 2025. The company maintains a strong cash runway into the second half of 2025. Sol-Gel also partners with Galderma for commercialization of dermatology products in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has initiated Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, aiming to prevent the development of new basal cell carcinoma (BCC) lesions in patients. The drug has 'Orphan Drug' and 'Breakthrough Therapy' designation status in the U.S. and E.U., with a potential market value of over $300 million. Sol-Gel is hosting a virtual Key Opinion Leader event on December 6th to discuss the patient experience, market opportunity, and Phase 3 trial design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) will host a virtual KOL event on December 6, 2023, to discuss preventing basal cell carcinomas associated with Gorlin syndrome. The event will feature discussions on the disease burden, SGT-610, and the upcoming Phase 3 trial. SGT-610, a new hedgehog inhibitor, has been granted Orphan Drug Designation and Breakthrough Designation by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences clinical trial
-
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announces plans to advance Orphan Drug candidate, SGT-610, for Gorlin syndrome into Phase 3 testing in late 2023. Financial results for Q3 2023 show a net loss of $5.7 million and a cash runway into the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
-
Rhea-AI Summary
Sol-Gel Technologies (NASDAQ: SLGL) to present at H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
Sol-Gel Technologies Ltd

Nasdaq:SLGL

SLGL Rankings

SLGL Stock Data

23.40M
7.56M
65.17%
28.59%
0.04%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
7 Golda Meir

About SLGL

sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th